<DOC>
	<DOCNO>NCT02569151</DOCNO>
	<brief_summary>Participants examine use method report previous . All chemical laboratory data obtain clinic visit morning non-fasting state . A single specimen visit use assess urinary albumin level base 2009 guideline ADA . CBP measure clinic visit . HBP measure every day morning within 10 minute awaken sit position , HBP value assess study use value measure morning clinic visit . Clinic hypertension ( CH ) morning hypertension ( MH ) define systolic BP ( SBP ) 130 mmHg and/or diastolic BP ( DBP ) 85 mmHg ; clinic normotension ( CN ) morning normotension ( MN ) define SBP &lt; 130 mmHg DBP &lt; 85 mmHg , respectively . The reason underlie threshold use clinic morning value base criterion 1999 WHO-International Society Hypertension guideline , study start 1999 . Based HBP , subject divide MH MN patient , anti-hypertensive drug use determine group . In addition , base CBP , subject divide CH CN patient . These patient follow use method use MH MN patient . Outcome consider first event subject . Primary end-point death cause . Secondary end-points new , worsen , improve microvascular macrovascular event . Risk factor relate outcome determine , therapy add baseline use disease patient MH record base- end-points . All result present mean ± SD . Mean value compare use pair unpaired student test . To compare prevalence event medical treatment patient without HT basis HBP CBP , Fisher 's exact test two-tailed P value use , hazard ratio 95 % confidence interval calculate . Differences outcomes patient HT NT basis HBP CBP base- end-points home clinic , respectively , assess use Kaplan-Meier survival curve compare hazard rate use log-rank test . Risk factor determine statistically relate outcome assess Cox proportional hazard analysis .</brief_summary>
	<brief_title>20 Years Results HBP DBP Patients With Type 2 Diabetes Mellitus After Following-up</brief_title>
	<detailed_description>Microalbuminuria clinical albuminuria define urinary albumin excretion rate 30 mg/g creatinine 300 mg/g creatinine , respectively ( 6 ) . CBP measure clinic visit . HBP measure every day morning within 10 minute awaken sit position , HBP value assess study use value measure morning clinic visit . Clinic hypertension ( CH ) morning hypertension ( MH ) define systolic BP ( SBP ) 130 mmHg and/or diastolic BP ( DBP ) 85 mmHg ; clinic normotension ( CN ) morning normotension ( MN ) define SBP &lt; 130 mmHg DBP &lt; 85 mmHg , respectively . . Microvascular complication include nephropathy , neuropathy , retinopathy . Severity nephropathy determine base albuminuria use four category : normal , 0 point ; microalbuminuria , 1 point ; clinical albuminuria , 2 point ; dialysis , 3 point . Severity neuropathy categorize normal , 0 point ; chronic sensorimotor distal symmetric polyneuropathy and/or cardiac autonomic neuropathy , 1 point . Severity retinopathy determine use four category : normal , 0 point ; simple , 1 point ; pre-proliferative , 2 point ; proliferative , 3 point . Development new , worsen , improve microangiopathy define accord change least one step baseline . Macrovascular complication include coronary heart disease , cerebrovascular disease peripheral artery obstruction . Severity macrovascular event categorize use two category : normal , 0 point ; coronary heart disease , cerebrovascular disease , peripheral artery obstruction , 1 point ( 3 ) . New , worsen ( recurrent ) , improved event define base clinical manifestation treatment throughout study . For ethical reason , patient treat various anti-hypertensive , anti-diabetic , anti-dyslipidemia , anti-hypercoagulation agent course study doctor . Outcome result consider first event subject ( 3 ) . Primary end-point death cause ( 3 ) . Secondary end-points new , worsen , improve microvascular macrovascular event ( 3 ) . 4 ) Risk factor assessment outcome . Risk factor end-point ? participant related outcome determine , therapy add baseline therapy use disease patient MH record base- end-points ( 3 ) . The 6-month interval minimize bias due fall rise HBP CBP measurement ( 10 ) . Statistical analysis . 1 ) Baseline . All result present mean ± SD . Mean value compare use pair unpaired student test . To compare prevalence micro- macrovascular complication medical treatment patient without HT basis HBP CBP ( 3 ) , Fisher 's exact test two-tailed P value use , hazard ratio 95 % confidence interval calculatein . End-points outcome measure . Differences outcomes end-point death , micro- macrovascular complication patient HT NT basis HBP CBP base- end-points home clinic , respectively , assess use Kaplan-Meier survival curve compare hazard rate use log-rank test . Risk factor assessment outcome . Risk factor determine statistically relate outcome assess Cox proportional hazard analysis . Analysis perform use Prism version software ( GraphPad Software , CA , USA ) Statistical Package Bioscience ( ComWorks Co , Tokyo , Japan ) . Two-tailed value P &lt; 0.05 consider statistically significant .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patients type 2 diabetes mellitus Patients type 1 diabetes mellitus disease except diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>